JP2006509497A - 神経発生に関する方法および物質 - Google Patents

神経発生に関する方法および物質 Download PDF

Info

Publication number
JP2006509497A
JP2006509497A JP2004539370A JP2004539370A JP2006509497A JP 2006509497 A JP2006509497 A JP 2006509497A JP 2004539370 A JP2004539370 A JP 2004539370A JP 2004539370 A JP2004539370 A JP 2004539370A JP 2006509497 A JP2006509497 A JP 2006509497A
Authority
JP
Japan
Prior art keywords
cells
wnt
cell
progenitor
dopaminergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004539370A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006509497A5 (https=
Inventor
アレナス，アーネスト
ワグナー，ヨセフ
ブランコ，ゴンサロ，カステロ
ソーサ，カイル
Original Assignee
ニューロ セラピューティクス エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0222162A external-priority patent/GB0222162D0/en
Application filed by ニューロ セラピューティクス エービー filed Critical ニューロ セラピューティクス エービー
Publication of JP2006509497A publication Critical patent/JP2006509497A/ja
Publication of JP2006509497A5 publication Critical patent/JP2006509497A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9413—Dopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1783—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Engineering & Computer Science (AREA)
JP2004539370A 2002-09-24 2003-09-24 神経発生に関する方法および物質 Pending JP2006509497A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41304602P 2002-09-24 2002-09-24
GB0222162A GB0222162D0 (en) 2002-09-24 2002-09-24 Methods and materials relating to neurogenesis
US49459503P 2003-08-12 2003-08-12
PCT/IB2003/004598 WO2004029229A2 (en) 2002-09-24 2003-09-24 Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands

Publications (2)

Publication Number Publication Date
JP2006509497A true JP2006509497A (ja) 2006-03-23
JP2006509497A5 JP2006509497A5 (https=) 2006-11-09

Family

ID=32045676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004539370A Pending JP2006509497A (ja) 2002-09-24 2003-09-24 神経発生に関する方法および物質

Country Status (6)

Country Link
US (2) US20060233771A1 (https=)
EP (1) EP1597355A2 (https=)
JP (1) JP2006509497A (https=)
AU (1) AU2003269354B2 (https=)
CA (1) CA2523618A1 (https=)
WO (1) WO2004029229A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011508760A (ja) * 2008-01-02 2011-03-17 サノフイ−アベンテイス ６−ヘテロ環式イミダゾ［１，２−α］ピリジン−２−カルボキサミド誘導体、この調製および治療用途
JP2012524727A (ja) * 2009-04-27 2012-10-18 オタワ ホスピタル リサーチ インスティチュート 幹細胞を調節するための組成物および方法ならびにその使用
JP2019106895A (ja) * 2017-12-15 2019-07-04 インダストリー‐ユニバーシティー コーぺレーション ファンデーション ハンヤン ユニバーシティ 神経幹細胞または神経前駆細胞からドーパミン神経細胞への分化方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1779867A4 (en) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd MEANS FOR PROMOTING NERVE REVENERATION
EP1791949A2 (en) * 2004-09-02 2007-06-06 Neuro Therapeutics AB Methods and materials relating to enhanced production of dopamine neurons
EP1827470A2 (en) * 2004-12-09 2007-09-05 Neuro Therapeutics AB Materials and methods related to dickkopfs (dkk) and neurogenesis
WO2006091766A2 (en) 2005-02-24 2006-08-31 Jau-Nan Lee Human trophoblast stem cells and use thereof
EP1871407A2 (en) * 2005-03-31 2008-01-02 The University Of Chicago Compositions comprising wnt-3 peptide for modulating medial-lateral neuronal topographic maps
WO2007119180A2 (en) * 2006-04-07 2007-10-25 Neuro Therapeutics Ab Survival and development of neural cells
WO2009011892A2 (en) * 2007-07-18 2009-01-22 Boston Biomedical Research Institute Use of suif proteins and heparan sulfate in gdnf-dependent neural innervation and protection
US20110244569A1 (en) * 2008-05-13 2011-10-06 Tara Louise Walker Method of inducing proliferation and/or differentiation of neural precursor cells by introducing prolactin or wnt3a to activate latent neural precursor cells
EP2352817B1 (en) * 2008-10-31 2016-01-27 University Of Louisville Research Foundation, Inc. Olfactory epithelial-derived stem cells and methods of use therefor
WO2012068170A2 (en) 2010-11-15 2012-05-24 Jau-Nan Lee Generation of neural stem cells from human trophoblast stem cells
TWI481715B (zh) * 2010-11-15 2015-04-21 Jau Nan Lee 從人類滋養層幹細胞中生成神經幹細胞
WO2013040341A2 (en) 2011-09-16 2013-03-21 Ottawa Hospital Research Institute Wnt7a compositions and methods of using the same
JP2014527818A (ja) 2011-09-16 2014-10-23 フェイト セラピューティクス，インコーポレイテッド Ｗｎｔ組成物およびそのような組成物の治療的使用
WO2014085493A1 (en) 2012-11-30 2014-06-05 Jau-Nan Lee Methods of differentiating stem cells by modulating mir-124
US9808490B2 (en) 2014-11-26 2017-11-07 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
KR101695429B1 (ko) * 2015-10-15 2017-01-12 한국과학기술연구원 생체외에서 운동 신경세포의 배양 촉진을 위한 코엔자임 q10을 포함하는 조성물
TWI772790B (zh) 2019-05-06 2022-08-01 美商加速生物科學有限公司 前驅調節滋胚內層細胞及其用途
CN114836386A (zh) * 2022-04-20 2022-08-02 电子科技大学 一种负载Wnt1蛋白且靶向脑组织的工程化外泌体及其制备方法和应用
WO2025193168A1 (en) * 2024-03-14 2025-09-18 National University Of Singapore Method of generating midbrain dopamine progenitors and neurons from stem cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06157554A (ja) * 1992-11-27 1994-06-03 Toray Dow Corning Silicone Co Ltd トリオルガノクロロシランの製造方法
US6277820B1 (en) * 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
US6610540B1 (en) * 1998-11-18 2003-08-26 California Institute Of Technology Low oxygen culturing of central nervous system progenitor cells
US6312949B1 (en) * 1999-03-26 2001-11-06 The Salk Institute For Biological Studies Regulation of tyrosine hydroxylase expression
DE60035191T2 (de) * 1999-05-03 2008-06-19 Neuro Therapeutics Ab Materialien und methoden zur entwicklung von dopaminergen neuronen
WO2001088100A1 (en) * 2000-05-16 2001-11-22 Kyowa Hakko Kogyo Co., Ltd. Novel method of inducing the differentiation of embryonic stem cells into ectodermal cells and use thereof
WO2001088104A2 (en) * 2000-05-17 2001-11-22 Geron Corporation Neural progenitor cell populations
US20020114788A1 (en) * 2000-07-27 2002-08-22 Ole Isacson Cell implantation therapy for neurological diseases or disorders
US20030211605A1 (en) * 2001-05-01 2003-11-13 Lee Sang-Hun Derivation of midbrain dopaminergic neurons from embryonic stem cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6009053449, Ｎａｔｕｒｅ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ，１９９９，Ｖｏｌ．１７，ｐ．６５３−６５９ *
JPN6009053450, Ｂｉｏｃｈｅｍ．Ｂｉｏｐｈｙｓ．Ｒｅｓ．Ｃｏｍｍｕｎ．，Ａｐｒ．２００２，Ｖｏｌ．２９３，ｐ．１６７−１７３ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011508760A (ja) * 2008-01-02 2011-03-17 サノフイ−アベンテイス ６−ヘテロ環式イミダゾ［１，２−α］ピリジン−２−カルボキサミド誘導体、この調製および治療用途
JP2012524727A (ja) * 2009-04-27 2012-10-18 オタワ ホスピタル リサーチ インスティチュート 幹細胞を調節するための組成物および方法ならびにその使用
US10071138B2 (en) 2009-04-27 2018-09-11 Ottawa Hospital Research Institute Compositions and methods for modulating stem cells and uses thereof
US10828346B2 (en) 2009-04-27 2020-11-10 Ottawa Hospital Research Institute Compositions and methods for modulating stem cells and uses thereof
JP2019106895A (ja) * 2017-12-15 2019-07-04 インダストリー‐ユニバーシティー コーぺレーション ファンデーション ハンヤン ユニバーシティ 神経幹細胞または神経前駆細胞からドーパミン神経細胞への分化方法
JP2022107819A (ja) * 2017-12-15 2022-07-22 インダストリー‐ユニバーシティー コーぺレーション ファンデーション ハンヤン ユニバーシティ 神経幹細胞または神経前駆細胞からドーパミン神経細胞への分化方法
JP7435942B2 (ja) 2017-12-15 2024-02-21 インダストリー‐ユニバーシティー コーぺレーション ファンデーション ハンヤン ユニバーシティ 神経幹細胞または神経前駆細胞からドーパミン神経細胞への分化方法

Also Published As

Publication number Publication date
AU2003269354B2 (en) 2008-03-06
US20090087417A1 (en) 2009-04-02
EP1597355A2 (en) 2005-11-23
US20060233771A1 (en) 2006-10-19
AU2003269354A1 (en) 2004-04-19
CA2523618A1 (en) 2004-04-08
WO2004029229A2 (en) 2004-04-08
WO2004029229A3 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
US20090087417A1 (en) Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands
Kele et al. Neurogenin 2 is required for the development of ventral midbrain dopaminergic neurons
Wang et al. Nogo-66 promotes the differentiation of neural progenitors into astroglial lineage cells through mTOR-STAT3 pathway
McGivern et al. Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production
Arsenijevic et al. Insulin-like growth factor-I is a differentiation factor for postmitotic CNS stem cell-derived neuronal precursors: distinct actions from those of brain-derived neurotrophic factor
JP6163104B2 (ja) ヒト・トロホブラスト幹細胞からの神経幹細胞の生成
Gascon et al. PSA-NCAM in postnatally generated immature neurons of the olfactory bulb: a crucial role in regulating p75 expression and cell survival
Schwartz et al. Stromal factors SDF1α, sFRP1, and VEGFD induce dopaminergic neuron differentiation of human pluripotent stem cells
Lee et al. tPA regulates neurite outgrowth by phosphorylation of LRP5/6 in neural progenitor cells
US7465582B1 (en) Nurr-1 induction of a dopaminergic neuronal fate in a neural stem cell or neural progenitor cell in vitro
Ma et al. Trophic and proliferative effects of Shh on motor neurons in embryonic spinal cord culture from wildtype and G93A SOD1 mice
Corvaglia et al. ProNGF is a cell-type-specific mitogen for adult hippocampal and for induced neural stem cells
WO2008071960A2 (en) Methods of increasing neurogenesis
JP2008511304A (ja) ドーパミンニューロンの増強産生に関する方法と材料
EP1827470A2 (en) Materials and methods related to dickkopfs (dkk) and neurogenesis
Zheng et al. Neuregulin regulates the formation of radial glial scaffold in hippocampal dentate gyrus of postnatal rats
JP2009532057A (ja) 神経細胞の生存および発生
AU2004202661B2 (en) Materials and methods relating to neuronal development
Kuan-Yin et al. MANF Is Essential for Neurite Extension and Neuronal Migration in the Developing Cortex
Ishan et al. Taste papilla cell differentiation requires tongue mesenchyme via ALK3-BMP signaling to regulate the production of secretory proteins
Ratzan Mechanisms that Pattern the Sensory Epithelia in the Developing Vestibular System
Hiester Determining the role of Wnt signaling during BDNF-induced cortical neuron growth and dendritic spine formation
Salih Investigating the existence of neural stem cells in the adult mouse cerebellum and third ventricle
Tervonen Differentiation of neural stem cells in fragile X syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100316